Category: Startup Funding News

Oister Global runs private-market funds that buy existing stakes in late-stage Indian startups, and it has now launched ACE Fund III with a target corpus of ₹500 crore, including a ₹250 crore greenshoe option. That matters because India has built a lot of startup wealth on paper, but actual liquidity between early funding rounds and public listings is still patchy. Founded in 2022 by Rohit Bhayana and Sandeep Sinha, the Gurgaon-based firm is betting that secondaries won’t stay a niche corner of venture finance much longer.

And this isn’t Oister’s first swing. Demand for its earlier vehicles was strong enough to justify a third dedicated fund, with domestic investors doing most of the heavy lifting.

What is ACE Fund III and how does it work?

ACE Fund III is a late-stage startup secondaries vehicle. Instead of writing fresh primary cheques into a company’s balance sheet, Oister buys existing shares from people who already hold them — founders, employees, early investors, or funds that want an exit before an IPO or strategic sale.

That changes the transaction in an important way. The company being bought into doesn’t necessarily raise new money. What changes is the shareholder base. Sellers get liquidity. The cap table gets cleaned up. A new investor gets exposure to a business that’s already operating at scale and is closer to a clear exit event.

Oister’s pitch to buyers is straightforward. It wants to invest in high-growth, late-stage companies that are profitable or near-profitable and have visible routes to liquidity through IPOs, strategic exits, or later funding rounds. The firm frames secondaries as a way to enter late but still get in early enough to capture value creation before a public-market or acquisition event resets pricing.

For investors, the structure is closer to curated access than a total black box. Oister has described its approach as giving backers directional visibility into the kind of businesses it intends to buy, while using an institutional six-step underwriting process to screen deals. In plain English: it’s trying to remove a lot of the messy manual work that usually comes with off-market stake transfers. That includes sourcing sellers and pricing private shares. It also means running diligence and figuring out whether there’s a real exit path or just a nice story.

Who founded Oister Global and how is it positioned?

The founding story

Oister Global was founded in 2022 by Rohit Bhayana and Sandeep Sinha. The firm was built on the investing base of Lumis, the platform both founders had already spent years building in India’s private markets. That part matters. Oister didn’t pop up as a first-time fund manager trying to surf a trend. It came out of an existing network of founders, GPs, family offices, and private-market relationships.

The strategy also makes sense in the context of where the Indian market is now. There are more mature startups. There are more long holding periods. And there’s more pressure on early backers to return capital.

Why the founders have market fit

Bhayana and Sinha aren’t career newsletter people pretending to be allocators. Bhayana earlier served as CEO of GE Software Solutions and has spent years investing and building through Lumis. Sinha’s background includes leadership at 3Com Technologies and the global technology leadership program at GE. Between them, they bring operator experience and long exposure to private-market dealmaking. That matters here.

Their wider investing track record is one of Oister’s biggest credibility signals. Across their broader careers, the founders have deployed more than $700 million across asset classes, launched 9+ funds, and backed 100+ portfolio companies. That doesn’t guarantee returns. But it does explain why Oister can show up as a buyer in sensitive secondary transactions where sellers care about confidentiality, speed, and cap-table fit.

What Oister has already done

Oister’s secondaries franchise has already invested in startups including BlackBuck, Servify, M1xchange, Kuku, and Purplle. Across the broader secondaries book, it has also backed names such as OfBusiness, Shiprocket, and BlueStone.

Half of ACE Fund I’s portfolio companies have already reached public-market outcomes through listings, DRHP filings, or exits. Those portfolio companies posted 32% year-on-year revenue growth and a 54% expansion in margins. Those are the numbers Oister wants prospective investors to focus on: not just liquidity, but liquidity into businesses that still look operationally healthy.

The fundraising details behind the new vehicle

The immediate headline is simple: ACE Fund III is targeting ₹500 crore, and that figure includes a ₹250 crore greenshoe option. The launch follows ACE Fund II, which was oversubscribed 2x and closed at ₹400 crore against its original target.

That takes total capital committed across the ACE franchise past ₹1,000 crore. Oister has also said that nearly 98% of the capital raised across the ACE series has come from domestic investors. That’s much higher than the average mix across India’s wider alternative investment fund market.

How Oister compares with other secondaries funds

This category is getting crowded, but not evenly crowded.

The most obvious large-format rival is 360 ONE Asset, which launched a much bigger ₹4,000 crore secondary fund to buy existing stakes from investors seeking liquidity. International specialists have also been active in India-focused secondaries, including TR Capital, Foundation Private Equity, and NewQuest Capital. So Oister isn’t alone in spotting the trade.

Its differentiation is narrower and more credible because of that. Oister is focused on late-stage private companies rather than trying to be everything to everyone across secondaries. It’s also focused on domestic capital and curated deal selection. Startup-specific cap-table situations, where timing matters a lot, are central to the pitch. Against legacy alternatives — waiting for an IPO, forcing a strategic sale, or arranging one-off off-market stake transfers through brokers — that’s a cleaner product.

Why ACE Fund III matters for startup liquidity

This third fund matters because it turns a one-off market need into a repeatable product. Founders and early investors in India have been stuck in an awkward middle zone for years: too mature for early-stage narratives, not always ready for the public market, and still carrying cap tables shaped by old rounds.

A dedicated secondaries pool gives them another option. Not emergency money. Not a down-round workaround. Just structured liquidity.

That can change behavior inside companies. Employees can sell some stock before an IPO. Seed and Series A funds can return capital without waiting forever. Founders can tidy up ownership without opening a fresh primary round they may not need. Newer investors get into a proven business with more operating history and a shorter route to exit than a typical early-stage bet.

Bhayana’s broader thesis is that secondaries in India are becoming an institutional-grade strategy, not just a liquidity side hustle. If he’s right, this launch won’t be remembered as just another fund close. It’ll look more like a sign that India’s private markets are finally building a real exit layer between venture rounds and public listings.

Why are India secondaries funds growing now?

The macro setup is doing a lot of the work.

India’s private markets absorbed roughly $429 billion of PE-VC investment between 2014 and 2024. A big chunk of that capital is now old enough to need exits. Bain has noted that about $108 billion invested from 2014 to 2018 has crossed the decade mark, while another $177 billion from 2019 to 2021 is moving into harvest mode. That’s a lot of inventory.

At the same time, exit timelines have stretched. The median IPO age has climbed from 6.9 years to 10.7 years over the last decade. That delay leaves founders, employees, and funds holding valuable but illiquid paper for longer than they expected. Secondaries step into that gap.

There’s also a scale argument. Oister estimates India’s annual secondary opportunity could reach as much as $20 billion. That doesn’t sound crazy anymore. Bain’s 2025 private equity work showed India hit about $33 billion in exits in 2024 and became Asia-Pacific’s biggest exit market by value. In the region more broadly, secondary transactions have already become the largest exit channel by value.

And one more thing. Domestic money is getting more comfortable with private markets. That’s important because local capital tends to understand founder behavior, listing cycles, and the weird timing of Indian exits better than distant allocators do. If that comfort keeps deepening, startup secondaries could move from occasional dealmaking to a standard portfolio-management tool.

Is ACE Fund III arriving at the right time?

It probably is.

The Indian startup market has enough mature companies now, enough delayed exits, and enough investor fatigue to support specialized liquidity funds that do one thing well. ACE Fund III is really a bet that startup liquidity itself is becoming a durable asset class in India. What to watch next is deployment discipline — not just whether Oister can write cheques, but whether it can keep buying into companies that are actually close to real exits.

Read how NanoCo raised a $12M seed round led by Valley Capital Partners to build NanoClaw, a security-first AI agent platform that runs tasks inside isolated containers instead of giving agents full machine access.

FAQ

– What is the size of ACE Fund III? 

 ACE Fund III is targeting ₹500 crore, and that number includes a ₹250 crore greenshoe option. It’s Oister Global’s third dedicated secondaries vehicle, launched after ACE Fund II closed at ₹400 crore and was oversubscribed 2x.

– How does Oister Global’s secondary fund model work? 

 Oister buys existing shares in late-stage private companies from current holders instead of putting fresh money directly into the startup. That gives liquidity to sellers such as founders, employees, or early investors. New backers get exposure to businesses that are typically closer to IPOs, strategic exits, or later-stage fundraising.

– How experienced are Oister Global’s founders? 

 Oister was founded in 2022 by Rohit Bhayana and Sandeep Sinha, both of whom came into it from Lumis and years of private-market investing. Bhayana previously led GE Software Solutions, while Sinha held senior roles at 3Com Technologies and earlier worked through GE’s leadership system.

– Why are startup secondaries becoming a bigger market in India? 

 Because India now has more mature startups than it has easy exit routes. With PE-VC investments from the last decade aging, IPO timelines stretching past 10 years on median, and an estimated $20 billion annual secondary opportunity, secondaries are becoming a practical way to create liquidity without forcing a new primary round or waiting indefinitely for a listing.

NanoCo builds NanoClaw, a security-first AI agent platform that runs tasks inside isolated containers instead of giving an agent the keys to your whole machine. Its $12 million NanoClaw funding round matters because the pitch isn’t “agents are cool” — it’s that enterprises want agents they can trust with real work. Founded in early 2026 by brothers Gavriel Cohen and Lazer Cohen, the company took off after a viral open-source launch and now has backing from Valley Capital Partners, Docker, Vercel, Monday.com, Slow Ventures, and Hugging Face CEO Clem Delangue.

What is NanoClaw and how does it work?

NanoClaw is an open-source AI assistant framework that routes messages from tools like WhatsApp, Slack, Telegram, Teams, Discord, email, and the terminal into a shared agent system. It then runs the actual agent session inside a sandboxed container. By default it uses Anthropic’s Claude Agent SDK, but it also supports other providers. It keeps memory, session state, and task scheduling attached to the right conversation instead of turning everything into one giant chat blob.

The security model is the whole point. Each invocation runs in an isolated Linux container with tightly scoped mounts and a non-root user. Execution is fresh and ephemeral. On macOS, NanoClaw can use Apple Container; on Docker, it can go a step further with Docker Sandboxes and microVM-style isolation. That means bash commands, file writes, and browser actions happen away from the host machine rather than behind a flimsy in-app permission prompt.

For a user, the workflow is pretty simple. You install the core system, run setup, connect only the channels you want, and let the platform route incoming requests to the right agent context. NanoClaw then handles memory files and workspaces. It also manages logs, task scheduling, and message delivery across channels. Shared sessions are supported too, so a conversation can move between, say, chat and webhook flows without losing state.

The newer layer is approval. Through its Vercel partnership, NanoClaw can surface native approval cards inside messaging apps when an agent wants to do something sensitive. That includes sending an email, making a payment, or deleting a cloud resource. That sounds mundane. It isn’t.

Who founded NanoCo and why did they build NanoClaw?

A startup born out of an internal need

NanoCo was founded in early 2026 by brothers Gavriel Cohen and Lazer Cohen after they ran into a problem inside their previous AI marketing startup. They were already using agents to do a lot of the work, but the available tools felt too exposed. NanoClaw started as their answer: a secure alternative to OpenClaw that kept agent behavior boxed into a container instead of letting it run straight on a computer with broad access to services and credentials.

The timeline was absurdly fast. Gavriel said it took “under six weeks from committing the first lines of code to a term sheet.” Before the company existed in any formal sense, the project had gone viral, drawn praise from Andrej Karpathy, and gotten an unexpected boost when Singapore’s foreign minister described NanoClaw as his “second brain.” The brothers also turned down a six-figure early offer to buy the project, then later rejected an acquisition proposal worth roughly $20 million.

Why the brothers had real market fit

Gavriel wasn’t some tourist founder who stumbled into AI because the category got hot. He previously worked at Wix, has academic training in physics and computer science, and had been doing deep after-hours AI tinkering before NanoClaw took off. That background helps explain why the project’s core pitch is architectural, not just branding. Smaller codebase. Tighter permissions.

Lazer came from the other side of startup building. He spent years in communications and built Concrete Media into a PR firm that helped launch more than 100 startups. That’s useful here in a practical way. Open source traction doesn’t automatically become a company. Someone still has to turn attention into customers, partnerships, and a story investors can underwrite.

Early traction, customers, and the NanoClaw funding round

The open-source community gave NanoClaw its first real proof point. The brothers say the product has many thousands of users, and NanoCo has already started signing enterprise customers after community members pushed the team toward a commercial offering. The company now has 10 employees and official partnerships with Docker and Vercel.

Enterprise demand is showing up in a specific way. Technical early adopters inside large companies set up NanoClaw for themselves, then coworkers started asking for the same thing. NanoCo’s answer is to sell implementation help — what the market now calls forward-deployed engineers — so customers can roll out AI agents to employees without turning one internal enthusiast into unpaid IT support. NanoCo wouldn’t name customers, but said executives at Amazon, Gap, Google, Meta, SentinelOne, and Accenture are already using NanoClaw.

On the capital side, Valley Capital Partners led the oversubscribed round, with Docker, Vercel, Monday.com, Slow Ventures, and Clem Delangue among the backers. That investor mix is telling. It isn’t just generalist venture money chasing a meme. Two of the participants sit directly inside the infrastructure and workflow stack NanoClaw is trying to own.

How NanoClaw compares with OpenClaw and other options

OpenClaw is the obvious comparison, and NanoClaw doesn’t hide from that. The whole product exists because the brothers liked what OpenClaw made possible but didn’t like the risk profile. NanoClaw’s differentiator is less about magical new agent intelligence and more about constrained execution. Smaller code footprint. OS-level isolation. Scoped mounts and auditable logs.

There are other ways to approach the same enterprise problem. A team can stitch together Claude Code or another agent framework, add a credential vault, bolt on approvals, and run the whole thing in Docker. But that’s still custom plumbing. NanoClaw is trying to package the hard part into something opinionated enough to deploy, while staying light enough that technical buyers can still understand it.

Why did NanoCo raise now instead of selling?

Because the company saw a chance to become infrastructure, not just code.

Rejecting the buyout offers signals that. If the founders thought NanoClaw was only a clever open-source wrapper, taking the money would’ve been rational. But the next step is enterprise deployment, support, and governance — the boring stuff that turns a viral developer project into a business. The forward-deployed engineer model points straight at that.

The round also gives NanoCo a way to commercialize without wrecking the thing that made NanoClaw popular in the first place. That matters. Open-source security tools die all the time when founders bury them under enterprise bloat. NanoCo now has enough capital to hire around support, approvals, and customer rollouts while keeping the core product lean.

And the cap table matters on its own. Docker’s involvement validates the sandboxing thesis. Vercel’s involvement validates the human-approval UX layer. Those aren’t random logos.

How big is the market for secure AI agents?

The wider agent market is getting big in a hurry. Grand View Research projects the global AI agents market will reach $182.97 billion by 2033, growing at a 49.6% CAGR from 2026. That kind of forecast deserves some skepticism, but it captures the direction of travel: businesses are moving from chatbots toward software that can take actions.

The cleaner signal is adoption inside enterprise software. Gartner said 40% of enterprise applications will feature task-specific AI agents by the end of 2026, up from less than 5% in 2025. In a separate 2026 survey, Gartner said only 17% of organizations had deployed AI agents so far, but more than 60% expected to do so within 2 years. That gap tells you what startups like NanoCo are selling into. Not a mature market. An impatient one.

There’s a catch. Gartner also predicted more than 40% of agentic AI projects will be canceled by the end of 2027 because of cost, weak business value, or inadequate controls. And that’s exactly where NanoClaw is trying to wedge itself in. Not at the model layer. At the trust layer.

Final take on NanoClaw funding

NanoClaw funding is interesting because it backs a constraint, not just a capability.

A lot of agent startups are still selling the dream that software can act like an employee. NanoCo is selling the less glamorous idea that the employee needs a badge, a locked office, and a manager who can say no. That’s a much better story for enterprise buyers.

Read how Imperagen raised a £5M seed round led by PXN Ventures to speed up enzyme engineering with a platform that combines quantum simulation, AI, and robotics to reduce lab-heavy trial and error.

FAQ

– What funding did NanoCo raise for NanoClaw?  

 NanoCo raised an oversubscribed $12 million seed round in May 2026. Valley Capital Partners led the deal, and the backers included Docker, Vercel, Monday.com, Slow Ventures, and Hugging Face CEO Clem Delangue.

– How does NanoClaw work?  

 NanoClaw routes requests from chat apps and other channels into an AI agent that runs inside an isolated container instead of directly on the host machine. It adds memory and scheduled tasks. It also handles channel routing and approval workflows so an agent can do useful work without getting broad unchecked access.

– Who are the founders of NanoCo?  

 NanoCo was founded in early 2026 by brothers Gavriel Cohen and Lazer Cohen. Gavriel came from engineering roles at Wix and built NanoClaw itself, while Lazer previously built Concrete Media, a PR firm that helped launch more than 100 startups.

– Is NanoClaw part of the enterprise AI agent market?  

 Yes. NanoClaw sits inside the enterprise AI agent category, but more specifically in the security and deployment layer for agents that need to operate across business tools and communication channels. That niche is getting attention as enterprises push beyond demos and demand isolation, approvals, and governance before broader rollouts.

Imperagen is an enzyme engineering startup that uses quantum simulation, AI, and robotics to design better enzymes faster. The Manchester company raised a £5 million seed round on Thursday. PXN Ventures led the deal, while IQ Capital and Northern Gritstone also participated. The pitch is simple: enzyme engineering is still too slow and too dependent on lab-heavy trial and error. Imperagen was founded in 2021 by Dr. Andrew Currin, Dr. Tim Eyes, and Dr. Andy Almond as a spinout from the University of Manchester’s Manchester Institute of Biotechnology.

What does Imperagen’s enzyme engineering platform do?

Imperagen’s product is a closed-loop enzyme engineering system. A customer starts with an enzyme problem — maybe they need a catalyst that works faster, survives harsher process conditions, or performs a very specific chemistry. Imperagen models that reaction at quantum-physics level, uses AI to prioritize promising variants, then tests those candidates in an automated lab before feeding the results back into the model. It’s a design-build-test-learn workflow, with a much heavier emphasis on mechanistic simulation than most AI protein tools.

That matters because lots of protein-design platforms still begin with sequence guessing and then rely on big rounds of wet-lab screening to see what sticks. Imperagen is trying to cut out a lot of that blind searching. Its system explores millions of mutation combinations in silico, then narrows the field before the physical work starts. It still needs experimentation. But each cycle should be more informed and less wasteful.

The company calls the underlying stack Digital Enzyme Evolution. On the lab side, it uses high-capacity robotics that can test up to a few thousand variants in a run. That’s where the feedback loop becomes useful instead of theoretical. Data from those experiments retrains problem-specific AI models, so the system gets better as it works through a customer’s exact chemistry instead of relying only on broad protein data.

It isn’t framed as a one-enzyme niche tool. Imperagen has already evaluated compatibility across multiple enzyme classes used in pharma and industrial biocatalysis, including oxidases, reductases, transaminases, and glucosidases. For customers, the promise is less “here’s an AI model” and more “here’s a faster way to get to a production-ready biocatalyst.” That’s a stronger commercial pitch if the science holds up outside the lab.

Who founded the enzyme engineering startup Imperagen?

Founded in Manchester to fix a stubborn chemistry problem

Imperagen came out of the Manchester Institute of Biotechnology, where the founding team had been attacking enzyme design from different angles. One stream was computational — advanced models that could screen huge mutation sets. The other was experimental — better ways to build and test enzyme variants in the lab. The founding idea was that combining those two approaches would beat the old method of repeated random mutation and screening.

That origin story fits the product. A lot of biotech startups bolt AI onto an existing workflow and call it a day. Imperagen seems to have been built around the workflow from day 1.

Why this founding team fits the job

Dr. Andy Almond, now CTO and co-founder, brings the clearest startup track record. He’s a biophysicist and previously co-founded C4X Discovery, which went public in 2014. That matters because Imperagen isn’t just a research project anymore. It needs somebody who understands how to turn hard science into a company people will actually buy from.

Dr. Andrew Currin, the company’s CSO and co-founder, is the deep technical anchor. He’s an expert in directed evolution and synthetic biology. He’s also credited with the patented gene-assembly technologies behind Imperagen’s automated platform. Tim Eyes, a co-founder who now serves as director of programs, came up through protein engineering, started his career in therapeutic biotech, and held an Enterprise Fellowship at the University of Manchester. The mix is tight. Biophysics, enzyme science, and protein engineering all map directly to a company trying to industrialize biocatalysis.

Fundraising, early signals, and where Imperagen sits against rivals

PXN Ventures led the new £5 million seed round, with IQ Capital and Northern Gritstone participating, and it takes Imperagen’s total funding to £8.5 million. On the same day, the company said Guy Levy-Yurista will become CEO, while the founding scientists stay in the business. Before this round, Imperagen had already picked up a £350,000 UKRI engineering biology award in March 2024 for work on its Digital Enzyme Evolution platform. That gave the science some external validation before the new capital arrived.

Competition is real, and it’s not all the same. Cradle is building a SaaS-style protein design platform and raised $73 million in late 2024 to expand its wet lab and software reach. Biomatter has pitched a more de novo, generative approach to enzyme design and raised a €6.5 million seed round to push that model further. Absci sits in a bigger, more therapeutics-heavy category, combining AI and synthetic biology with a large wet-lab data engine for protein drug creation. Imperagen’s angle is narrower and more practical: it’s focused on industrial biocatalysis and enzyme engineering problems where mechanistic chemistry, robotics, and real manufacturing constraints matter more than flashy sequence generation alone. The legacy alternative isn’t another startup. It’s directed evolution by hand, contract labs, and long development cycles.

Why does this enzyme engineering startup funding matter?

This round matters because it looks like a shift from spinout science to company-building. Imperagen said the new money will go into hiring more AI specialists, expanding R&D, building out experimental lab capacity, and creating a go-to-market function over the next 2 years. This isn’t a keep-the-lights-on raise. It’s a build-the-machine raise.

The CEO hire is part of that. Levy-Yurista comes in with a background across AI, life sciences, and enterprise technology, and his brief isn’t subtle: build a vertical AI infrastructure for biocatalysis, sharpen commercial models, and add industrial partnerships. Investors aren’t just betting on better models. They’re betting on a company that can package those models into a repeatable product.

His framing is also more grounded than a lot of biotech AI talk. He’s argued that many AI-led enzyme tools can beat trial-and-error in theory but still fail when pushed to industrial scale in practice. So the pitch here isn’t magic. It’s to make enzyme development “faster, more reliable, and more commercially accessible,” helping companies bring bio-based products to market without the usual delay and uncertainty.

How big is the market for AI enzyme engineering?

The commercial backdrop is big enough to get investor attention. Grand View Research estimated the global engineered enzymes market at $2.78 billion in 2024 and projects it to reach $7.32 billion by 2033, which implies an 11.6% CAGR. In the U.S. alone, the broader enzymes market was estimated at $3.8 billion in 2023, with projected annual growth of 6.7% through 2030.

The demand drivers are pretty clear. Pharma needs more selective catalysts for drug manufacturing. Food and agriculture keep looking for cleaner processing tools. Industrial chemistry is under pressure to lower energy use and swap out harsher reaction conditions where it can. Enzymes sit right in the middle of that shift, which is why so many techbio companies are piling into protein design right now. The hard part isn’t explaining why the market exists. It’s proving a platform can deliver enzymes that survive real production environments, not just elegant demos.

Can Imperagen turn enzyme engineering into software?

That’s the bet.

Imperagen has the ingredients investors usually want in a deep-tech biotech company: scientific depth, a founder team with domain credibility, a new CEO brought in for commercial scale, and a product story that goes beyond generic “AI for biology” claims. But this category is unforgiving. If the company can show that its closed-loop platform consistently produces enzymes that work on industrial timelines and economics, this enzyme engineering startup could become one of the more interesting biocatalysis companies to watch over the next 24 months.

Read how Stilta raised a $10.5M seed led by Andreessen Horowitz to automate the repetitive research and analysis behind patent litigation with AI agents that generate claim charts, prior art searches, and case-ready legal reports.

FAQ

– What funding did Imperagen raise? Imperagen raised a £5 million seed round announced on Thursday. PXN Ventures led the deal, and IQ Capital plus Northern Gritstone joined in. The raise brings the company’s total funding to £8.5 million and is meant to support hiring, R&D, lab expansion, and commercial buildout.

– How does Imperagen’s platform work? It works as a closed-loop enzyme engineering system that combines quantum-level simulation, AI ranking, and robotic lab testing. Instead of mutating enzymes mostly by trial and error, Imperagen models likely outcomes on a computer first, tests the best candidates in the lab, and feeds that experimental data back into the model for the next round.

– Who founded Imperagen? Imperagen was founded in 2021 by Dr. Andrew Currin, Dr. Tim Eyes, and Dr. Andy Almond, all scientists tied to the Manchester Institute of Biotechnology. Their backgrounds span directed evolution, protein engineering, synthetic biology, and biotech company creation, which is why the founding team looks credible for this very specific problem.

– What market is Imperagen in? Imperagen sits in enzyme engineering and industrial biocatalysis, with overlap into techbio and AI-driven protein design. Its target customers are companies using enzymes in pharmaceuticals, food, biofuels, agriculture, and other manufacturing workflows where better catalysts can cut time, cost, and process complexity.

Stilta is building patent litigation software that automates the heavy research and analysis behind intellectual property disputes. The startup raised a $10.5 million seed round led by Andreessen Horowitz, with backing from Y Combinator and operators linked to OpenAI, Legora, and Lovable. Patent litigation still involves large amounts of repetitive review work. That process is often slow, expensive, and difficult for companies to pursue. Founded in 2026 by Oskar Block, Tobias Estreen, Petrus Werner, and Oscar Adamsson, Stilta wants to turn that bottleneck into software.

What is Stilta and how does the patent litigation software work?

Stilta’s patent litigation software starts with a simple input: a patent number and any supporting material the lawyer wants to add. From there, its AI agents break down the claims and search for conflicting patents and other relevant references. They also pull prosecution and court history, then assemble a report with claim charts and source-level support that a legal team can actually use in a case file.

The product is more technical than the usual “legal copilot” pitch. Petrus Werner, Stilta’s co-founder and CTO, described a system that runs in secure, isolated Kubernetes environments and combines base agent tools like file access, terminal work, and code generation with litigation-specific workflows. The agents operate on a data layer that spans more than 170 million patents from 100-plus jurisdictions. It also includes US and European prosecution and litigation history, 250 million scientific publications, and internet archive material reaching roughly 1 trillion web pages.

For attorneys who don’t want a black box, the customer experience looks deliberate. Stilta frames the software as attorney-led, not autonomous. Users can steer the analysis, test different theories, and inspect the evidence trail rather than accept a single generated answer. That matters.

Who founded Stilta and why did they build it?

A dinner-table idea turned into a company

The founding story is unusually direct. Block had already started one company at 18, building machine learning models for sports betting, then moved into consulting work around AI adoption before taking a role at an autonomous trucking company. There, he got a close look at how manual the patent process still was. The real spark came over dinner with Estreen, when Estreen’s father — a patent attorney — described a workday full of repeated document review done the same way for decades. That conversation led Block and Estreen to pull in Werner and Adamsson and launch Stilta.

Why this team has some real market fit

Block’s background matters because he’s not coming at this as a pure legal outsider who just discovered AI agents last month. He’d already spent time on hard data problems, enterprise AI integration, and applied automation inside a complex industrial company. That gives him some credibility when the pitch is less “AI for lawyers” and more “AI for high-stakes, evidence-heavy workflows.”

The broader founding team also fits the category well. Stilta describes the four founders as engineers from McKinsey and QuantumBlack who spent years deploying secure AI systems for demanding enterprise customers. Werner is listed as co-founder and CTO. The company’s early messaging makes clear that the group is trying to sell not just model capability, but enterprise reliability and auditability.

Early traction, status, and the seed round

For a very young company, Stilta is already giving off more than slide-deck energy. Y Combinator lists it as an active W26 startup founded in 2026 with a team size of 4. Stilta already works with some of the largest IP firms in the world and with several Fortune 500 enterprises. It has also been welcomed into Mannheimer Swartling’s innovation lab in Sweden.

The financing is a $10.5 million seed round announced on Tuesday, and Andreessen Horowitz led it. Alongside a16z, the cap table includes Y Combinator and operators from OpenAI, Legora, and Lovable. The company hasn’t laid out a detailed public spending plan, but the open roles across engineering, design, go-to-market, and patent expertise make the likely priorities obvious.

How Stilta stacks up against competitors

Stilta isn’t alone. Solve Intelligence and DeepIP are two clear comparables, but they aren’t identical businesses. Solve Intelligence leans heavily into invention harvesting and patent drafting. It also covers prosecution and prior-art analysis. DeepIP pitches a broader end-to-end patent workflow covering invention capture, drafting, prosecution, risk assessment, agentic search, portfolio intelligence, and landscaping.

Stilta’s angle is narrower and sharper: litigation and dispute work. That focus matters. Instead of trying to be the operating system for every patent task, it’s going after infringement and invalidation research where the output has to be argument-led, traceable, and usable under real pressure. The legacy alternative here isn’t just older software. It’s armies of lawyers and analysts doing manual review, plus commercial search tools that often stop at retrieval instead of building a case theory.

There’s also a speed-and-quality claim behind the pitch. In a test on 40 real PTAB institution decisions, Block said Stilta reached 71% petition recall in 20 to 30 minutes, compared with 18% for general-purpose LLMs and roughly twice the median performance of five large commercial patent search tools. That’s still a company-run benchmark. Take it as directional, not gospel.

Why are investors backing this patent litigation software startup?

This seed round matters less because of the dollar amount and more because of what it validates. Patent work is a brutal category for new software. Buyers are cautious, evidence standards are high, and the cost of a wrong answer is a lot higher than in lighter legal workflows. So when a16z leads a seed here — with YC and a network of well-known operators around the deal — it reads like a bet that patent-specific legal AI is ready to move past novelty.

It also gives Stilta a shot at turning early access into actual market share before the category gets crowded. The company is already hiring across engineering, product-adjacent patent expertise, and GTM roles in Stockholm and New York. The immediate job isn’t inventing a new narrative. It’s expanding deployment, tightening product reliability, and proving that specialized patent intelligence software can earn trust inside top-tier firms and enterprise legal teams.

There’s a subtler reason this round matters. If the product works the way Block says it does, the addressable customer isn’t only outside counsel. It includes companies sitting on patents they’ve never enforced, licensed, or properly analyzed because the economics never made sense before.

How big is the market for patent litigation software and legal AI?

The market backdrop is straightforward: there’s more IP to analyze, and legal buyers are finally spending real money on AI. WIPO said innovators filed a record 3.7 million patent applications worldwide in 2024, up 4.9% from 2023 and nearly double the level seen in 2010. More patents in the system means more prior-art work and more portfolio review. It also means more opportunities for disputes.

On the software side, Grand View Research estimated the global legal AI market at $1.445 billion in 2024 and expects it to reach $3.918 billion by 2030, a 17.3% CAGR. The broader global legal technology market was estimated at $28.7 billion in 2025 and is projected to hit $69.7 billion by 2033. Those numbers won’t map cleanly to patent litigation tools alone, but they show why investors are circling legal workflows that were considered too specialized a few years ago.

The adoption curve is moving too. Thomson Reuters said average law firm spending on technology and knowledge management rose 9.7% and 10.5%, respectively, on top of already elevated 2024 growth. It also found firms with a visible AI strategy were 3.9 times as likely to report at least one form of ROI. So the timing here isn’t random. Legal buyers are no longer just experimenting. They’re budgeting.

Final take on patent litigation software

Stilta is still early. Very early.

But this isn’t one more generic legal AI wrapper dressed up in patent language. The company is making a focused bet that patent litigation software should behave less like search and more like a coordinated research team. It should build arguments, surface evidence, and leave the attorney in control. If that holds up outside founder demos and early design partners, the next question is whether Stilta becomes a specialist tool for elite firms — or the default workflow for a much larger chunk of IP litigation.

Read how Ocean raised $28M led by Lightspeed Venture Partners to build agentic email security software that investigates suspicious messages before employees interact with them.

FAQ

– What funding did Stilta raise? 

 Stilta raised a $10.5 million seed round. Andreessen Horowitz led the round, and the investor list also includes Y Combinator plus operators connected to OpenAI, Legora, and Lovable.

– How does Stilta’s patent litigation software work? 

 It takes a patent number and supporting materials, then uses AI agents to analyze claims and search for prior art and related evidence. It also pulls filing and court history, then generates reports and claim charts with traceable support. The system is built for interactive attorney review rather than one-click automation.

– Who founded Stilta? 

 Stilta was founded in 2026 by Oskar Block, Tobias Estreen, Petrus Werner, and Oscar Adamsson. Block is the CEO, Werner is the CTO, and the team’s background includes enterprise AI work at McKinsey and QuantumBlack, plus Block’s earlier startup, consulting, and autonomous trucking experience.

– Is patent litigation software part of a big market? 

 Yes. It sits inside a fast-growing legal AI and legal tech category, with the legal AI market estimated at $1.445 billion in 2024 and projected to reach $3.918 billion by 2030, while global patent filings hit 3.7 million in 2024. That mix of rising software spend and rising IP volume is why startups like Stilta are getting funded now.

Ocean builds agentic email security software that investigates incoming messages before employees act on them. The startup has now come out of stealth with $28 million in total funding as email fraud gets sharper, cheaper, and more personalized in the age of generative AI. Founded in 2024 by Shay Shwartz and Oran Moyal, Ocean is pitching a blunt idea: old email defenses were built to spot suspicious patterns, while newer attacks are designed to look perfectly normal.

That pitch has landed with investors. Lightspeed Venture Partners led the round, with Picture Capital and Cerca Partners joining in, plus an angel list that includes Wiz co-founder and CEO Assaf Rappaport and Armis co-founders Yevgeny Dibrov and Nadir Izrael. Ocean is already processing more than 1 billion emails a month and protecting hundreds of thousands of mailboxes.

What is Ocean’s agentic email security platform?

Ocean’s agentic email security platform is built around an investigation engine called Ray. In practice, a customer plugs Ocean into Microsoft 365 or Google Workspace through an API, and the system starts reviewing inbound email in real time before the message becomes someone else’s problem. It doesn’t just score for spammy signals and checks sender identity and message content. It also reviews links, technical infrastructure, and the business context around the conversation to decide whether the email can actually be trusted.

The product is more specific than the usual “AI platform” pitch. Ray coordinates a set of purpose-built agents, including identity, link, file, infrastructure, financial, contact, quarantine, and abuse-mailbox agents, that follow evidence from different angles. The platform also builds what it calls a living memory of how an organization normally communicates. That’s meant to help it spot subtle impersonation, vendor fraud, and business email compromise that sail past standard filters.

That matters because Ocean isn’t only trying to block bad email at the front door. It also automates the follow-up work that burns security teams out: triaging employee-reported phishing emails and handling quarantine-release requests. It also runs deeper incident-response investigations without forcing analysts into endless manual review. Ocean’s framing is simple: employees get fast answers, while the SOC gets time back.

For customers, the pitch is less about another dashboard and more about replacing hand-built security operations around email. Before, a team might rely on a secure email gateway and a patchwork SOAR playbook. A lot still comes down to analyst judgment. After Ocean, the company wants each message to arrive with an explainable verdict instead of a vague risk score. That’s a strong promise. It only holds up if false positives stay low.

Who founded Ocean and why build it now?

The founding story

Ocean was founded in 2024 by CEO Shay Shwartz and CTO Oran Moyal. The two go way back — they first knew each other as teenagers and later reunited to help build a joint cyber unit serving the Israel Defense Forces and Shin Bet. They spent 4 years leading major projects there, won personal honors, and were part of work that earned the Israel Security Award.

Shwartz’s route into cybersecurity wasn’t exactly polished. He has said he made money as a teenage hacker, got caught at 16, and then decided to put the same skills to work on defense instead of offense. That turned into roughly a decade in elite cybersecurity roles, including work tied to the Iron Dome project, before he moved into the startup world. The backstory is messy. It’s more believable for it. This isn’t a founder who discovered phishing from a market map. He’s spent years thinking like an attacker.

Why these founders fit the problem

After military service, Shwartz joined Axis Security, the startup later acquired by HPE. Moyal took a different path: first VisibleRisk, which was later acquired by BitSight, and then Microsoft, where he helped create a group focused on finding security weaknesses in Azure cloud products. That’s a direct line into Ocean’s thesis. One founder understands offensive tradecraft and enterprise go-to-market from Axis. The other has deep platform and cloud security experience from Microsoft.

Both founders argue that AI broke the economics of spear phishing. Shwartz put it plainly: “AI just made the entire process automatic, so the scale is much, much bigger now.” He also described how an LLM can profile a target from public data and generate a highly tailored attack fast. That’s the company’s whole origin story in one sentence — once personalization becomes cheap, email defense has to shift from pattern matching to context analysis.

Traction, fundraising, and early execution

Ocean launched from stealth in May 2026, but it isn’t pre-product. The company is live, employs about 35 people, and already serves customers including KAYAK, Kingston Technology, and Headspace. It also works inside Fortune 500 environments. Public reporting says Ocean has reached seven-figure revenue, processed more than 1 billion emails in its first year, and now handles more than 1 billion each month.

The funding stack is more interesting than the headline suggests. The company has raised $28 million in total. CTech reported that the latest financing is a $20 million Series A, following an $8 million seed round in 2024 led by Picture Capital. Lightspeed led the new round, with Picture Capital and Cerca Partners participating, plus angels from Wiz, Armis, Axis, Island, and Transmit. Ocean plans to use the cash to expand AI research and speed up product development. It also plans to triple headcount within a year.

How Ocean’s agentic email security compares with Proofpoint, Mimecast, and Abnormal

This is where Ocean is trying to wedge itself into a crowded category. Proofpoint and Mimecast still represent the legacy backbone for a lot of enterprise email security, often through secure email gateway deployments and layered threat protection. Abnormal Security, by contrast, built its name on cloud-native behavioral detection for business email compromise and impersonation attacks.

Ocean’s bet is that even those newer approaches aren’t enough once attackers use AI to mimic ordinary business traffic with almost no obvious anomalies. So instead of selling itself as better detection, it sells “autonomous investigation.” That’s the distinction investors seem to be buying: not another model that flags weird messages, but a system that tries to reason through whether a legitimate-looking email is asking for the wrong thing. It’s a subtle difference on paper. In production, it could be a real one.

Why does Ocean’s $28M round matter?

Because this isn’t just a branding round.

Ocean is using the money to do 3 concrete things: add more AI research and build out the platform faster. It also plans to dramatically expand the team. For customers, that usually means one thing — the company is trying to move from “promising stealth startup” to a vendor that can survive procurement, scale support, and handle bigger enterprise rollouts.

The round also shows what investors think the next email security battle looks like. Lightspeed and Picture Capital didn’t back a compliance layer or a lightweight email add-on. They backed a team with offensive cyber experience that argues intent matters more than indicators. If that thesis is right, Ocean could become less of a phishing filter and more of an always-on investigation layer for enterprise communications.

There’s another signal here. Ocean already has recognizable customers, meaningful email volume, and live deployments while still young. That makes the round feel less like a speculative AI bet and more like acceleration capital for a product that has already found a wedge.

Why is agentic email security getting funded now?

The market backdrop is clear. Grand View Research estimates the global phishing protection market was worth $2.48 billion in 2024 and projects it will reach $7.16 billion by 2033, a 12.8% CAGR. Email-based phishing was the biggest sub-segment, and large enterprises accounted for 71.9% of revenue share in 2024. So yes, this is a real budget line, not a science project.

The loss data is even harsher. The FBI’s 2025 IC3 report logged 24,768 business email compromise complaints and $3.05 billion in reported losses in the U.S. alone. That’s why startups like Ocean can get attention fast: if attackers can now use AI to write clean, contextual, convincing messages, the cost of a miss climbs way past the cost of another security tool.

Ocean may be early, but the timing isn’t random. The broader industry is already shifting from static rules and reputation checks toward behavioral analysis, context, and real-time judgment. Agentic email security is basically the next version of that argument. Software doesn’t just detect risk. It investigates it.

Can Ocean’s agentic email security actually break out?

It might.

The founders have the right scars for the problem, the early customer list is credible, and the product thesis feels sharper than the usual “AI for security” slogan. But email security is brutal. Buyers care about efficacy, false positives, deployment pain, and whether a new vendor can survive the grind of enterprise sales.

The next thing to watch is whether Ocean’s agentic email security can keep winning live replacements against entrenched tools once the pilots turn into annual contracts.

Read how Status AI raised $17M across seed and Series A to build an AI-powered social gaming app where users role-play inside simulated fandom-driven social networks.

FAQ

– What funding has Ocean raised?  

 Ocean has raised $28 million in total funding. The company emerged from stealth on May 19, 2026, and reporting around the launch says the latest round was a $20 million Series A led by Lightspeed Venture Partners after an $8 million seed in 2024.

– How does Ocean’s agentic email security work?  

 Ocean plugs into Microsoft 365 and Google Workspace and investigates incoming messages in real time through an engine called Ray. It uses multiple AI agents to examine identity and links. It also reviews files, infrastructure, and business context, then returns an explainable verdict instead of a generic threat score.

– Who are Ocean’s founders?  

 Ocean was founded in 2024 by Shay Shwartz and Oran Moyal. Shwartz came from elite Israeli cyber and defense roles and later joined Axis Security, while Moyal worked at VisibleRisk and then Microsoft, where he focused on security gaps in Azure cloud products.

– Is Ocean in the email security market or the phishing protection market?  

 It sits in both, but its closest category is enterprise email security focused on phishing, impersonation, and business email compromise. That puts it inside a phishing protection market that Grand View Research sized at $2.48 billion in 2024, with growth expected through 2033.

Status AI is an AI social gaming app that lets people role-play as original or fandom characters inside a simulated social network. Status AI funding reached $17 million across seed and Series A on Tuesday, May 19, 2026, as investors backed a blunt thesis: younger users are getting bored of passive feeds and want entertainment they can actively inhabit. CEO Fai Nur started building the company in 2022 after ChatGPT launched, teaming up with Amit Bhatnagar and Pritesh Kadiwala to turn online fandom behavior into a product. The app came out of stealth in 2025, and its pitch is simple enough to spread fast — don’t just follow a story, step inside it.

What is Status AI and how does it work?

Status works like a mash-up of social media, fanfiction, and RPG mechanics. A player starts a scenario in solo mode or multiplayer, picks a character from thousands of fandoms or creates an original one, then begins posting and replying. DMs and relationship-building happen inside an AI-populated feed. Each scenario can include up to 100 characters, so the experience isn’t a one-on-one chatbot thread — it’s a crowded social world.

The setup is more detailed than a lot of AI character apps. Users assign a name, handle, image, bio, description, and traits. Status separates a character’s short personality summary from the deeper behavioral prompt that shapes how they act publicly, who they like, and how they talk. That matters.

The product is built around visible social behavior, not just private dialogue. The game loop adds structure that most chatbot apps still don’t have. Posts and replies feed into progression. So do daily activities, random events, side quests, and XP. When you level up, you earn skill points and unlock more scenario options. You also change how the world responds to you. Status tracks relationship shifts, follower counts, humor, and aura. It turns role-play into a stats-driven system instead of an endless text box.

Status also removes a lot of manual fandom labor. Instead of juggling Discord RP servers, Tumblr threads, fanfic notes, and scattered chatbot sessions, the app generates prompts and side characters. It also generates narrative beats and consequences in one place. Status’s product pages frame that as shared timelines and persistent memory. User reviews point to the same thing: the app remembers past events, adapts to the character you built, and keeps the story moving without forcing the player to orchestrate every scene alone.

Who founded Status AI and why did they build it?

A fandom-native founding story

Nur’s origin story for the company is pretty clear. She has described herself as a “chronically online teenager,” and when ChatGPT arrived in 2022 she saw a way to turn fandom immersion into an actual consumer product. She pulled in Bhatnagar — who grew up building Minecraft games — and Kadiwala, and the three started building Status as a social app where users could play any character in any universe.

Why this team has some market fit

The founders weren’t coming in cold. They had already been building consumer apps through WishRoll, the startup behind Status. Kadiwala later described the company’s engineering style as a modular, microservices-heavy stack built for quick launches and constant experimentation. That makes sense for a product category where user taste changes fast and inference costs can wreck the business.

WishRoll’s earlier app, Kiwi, gives the team some proof that it knows how to make youth-oriented consumer software travel. Kiwi passed 2 million downloads. It hit the No. 1 iOS app spot in Spain in January 2023 and France in August 2022. Y Combinator lists Status as a New York company from the Winter 2022 batch with a team size of 9.

Traction, launch timing, and the round itself

Status came out of stealth last year and is already showing the kind of engagement numbers that get consumer investors interested. Nur said users have created more than 13 million worlds and more than 5 million character profiles. Separate company materials put Status above 3 million users worldwide. An infrastructure partner case study said the app scaled to more than 500,000 daily active users after its February 2025 full release and logged average daily playtime of 1 hour and 36 minutes. Big numbers.

The funding is a combined seed and Series A totaling $17 million. Investors include Abstract, General Catalyst, Union Square Ventures, Y Combinator, and LightShed Partners. The company will use the money to scale the platform. That tracks with the product itself, because a multiplayer, memory-heavy, always-on simulation is basically an infrastructure bill disguised as entertainment.

How Status compares with Character.AI and Chai

The direct comps are obvious. Character.AI popularized AI character chat at massive scale, raising $150 million in Series A funding at a $1 billion valuation in 2023 before later signing a Google licensing deal in August 2024. Reuters said the company had previously raised $193 million in venture capital. Chai, another major player in AI chat companions, said in July 2025 that it had raised more than $55 million in total, served over 10 million users, and reached $40 million in ARR.

But Status isn’t really trying to win on the same axis. Character.AI is strongest in private, one-on-one conversation. Chai is built around user-generated bots and monetized chat. Status pushes the interaction out into public view — timelines, replies, social reputation, follower growth, multiplayer storylines, and persistent consequences. The older alternatives aren’t just AI apps, either. They’re fanfic forums and RP communities. Conventional feeds too, where fandom mostly sits on top of the product instead of driving the whole thing.

Why does Status AI funding matter right now?

The obvious reason is scale. Status has already had to wrestle with the ugly economics of consumer AI, and the company’s infrastructure partner said it cut AI costs by more than 95% while supporting sub-second responses and heavy load. Nur has also said the goal is to push cost down to just a few cents per user per day. That’s the unglamorous part of the story, but honestly it’s the part that matters most. Consumer AI apps don’t die because people hate them. They die because the bill arrives.

There’s also a product thesis inside this round. Nur argues that first-wave AI social apps already feel dated because they center the chatbot. Her bet is that the next thing people want is a story world with social mechanics attached to it. Rich Greenfield at LightShed made the media angle even clearer, saying media companies are desperate to get consumers to live inside the worlds and characters they create. If Status can become the mobile layer where fandom turns into repeat behavior, that’s a much bigger business than “another AI app.”

A sharper demographic signal runs through this round too. Nur says the earliest users were predominantly young women. That’s not a throwaway line. A lot of social products get dismissed when their first power users are teenage girls or fandom-heavy communities, right up until those same communities decide what breaks into mainstream culture. Natalie Dillon of Maveron has argued that the next winning social products will feel more like multiplayer environments than traditional networks. Status fits that thesis almost too neatly.

How big is the market for AI social gaming?

The market data says investors aren’t making a tiny niche bet. Grand View Research estimates the global AI in gaming market was worth $3.28 billion in 2024 and projects it will reach $51.26 billion by 2033, a 36.1% CAGR. Non-player character behavior modeling was the biggest application segment in 2024, accounting for 25.1% of revenue, and North America held roughly 35% of the market. Status sits right on top of those trends: AI characters, mobile-native play, and personalized social interaction.

The entertainment trend is just as important. Deloitte says younger audiences are spreading their attention more evenly across TV and streaming, social media, and gaming, while the future of media is being shaped by the convergence of film, games, and social video. That sounds abstract until you look at Status. The whole product is built as a consumer layer between fandom, gameplay, and IP expansion. It sits at the intersection legacy media companies are now chasing because passive viewing no longer owns as much time as it used to.

Can Status AI turn fandom into a durable business?

Maybe. But this is still a hard company to build.

The upside is obvious: Status has real engagement and a product that feels different from chatbot incumbents. The founder story also matches the audience. The hard part is keeping compute, moderation, and IP complexity from swallowing that momentum. Status AI funding buys the team time to prove this can be more than a novelty app. The next test is whether multiplayer storytelling and studio relationships turn into something sticky enough to survive after the first burst of curiosity wears off.

Read how Trackk raised a $3.7M seed round led by Lightspeed to build a simpler stock discovery and trading platform for Gen Z investors in India.

FAQ

– What is the Status AI funding amount? 

 Status AI raised $17 million in combined seed and Series A funding. The company announced the round on Tuesday, May 19, 2026, with backing from Abstract, General Catalyst, Union Square Ventures, Y Combinator, and LightShed Partners.

– How does Status AI work? 

 Status lets you create a persona, join or build a scenario, and interact with AI characters through posts and replies. It also uses DMs, events, and multiplayer storylines. The app layers in XP and side quests. Relationship changes and follower growth make it behave more like a social simulation game than a plain chatbot.

– What is the background of Status AI’s founders? 

 Status AI was built by Fai Nur, Amit Bhatnagar, and Pritesh Kadiwala after Nur saw ChatGPT’s potential in 2022. The team had already been building Gen Z consumer apps through WishRoll, including Kiwi, and Kadiwala has spoken publicly about the modular engineering system that helped the company launch and test products quickly.

– Is Status AI a social media app or an AI game? 

 It’s basically both. Status presents itself as a “sims but social media” product, mixing a Twitter-like feed with character role-play and RPG progression. Shared timelines and multiplayer are part of it too, which is why the company calls the category “immersive social entertainment.”

Trackk is a Mumbai-based stock discovery and broking app for young Indian investors. The Trackk trading app has raised $3.7 million in a seed round led by Lightspeed, with participation from Info Edge Ventures. The startup wants to make investing simpler for Gen Z users. Many young investors discover stock ideas through creators, communities, and social media. However, most trading platforms still feel too complex for beginners. Founded in 2021 by Vedant Gupte, Siddharth Thakkar, and Aryan Jain, Trackk is now expanding into a broader multi-asset investing platform. Its early user base mainly includes people between 20 and 24 years old.

What does the Trackk trading app actually do?

The easiest way to understand Trackk is this: it tries to compress stock discovery and research into one mobile-first flow. Execution sits in the same experience. A user can search for a stock, read a simple report, check its risk profile, review company signals, and place trades without switching between multiple tabs or complex dashboards. That’s the core product bet.

Its stock-report layer is unusually specific for a youth-focused investing app. Trackk shows a 1-to-10 “Trackk Score,” a volatility meter, a profit consistency tracker, an event sensitivity index, promoter holding data, and a simple SWOT breakdown in one view. It also offers a clear buy, hold, or sell call, plus target and stop-loss cues. That’s its answer to the spreadsheet-and-Telegram chaos that still defines a lot of retail stock discovery in India.

The app also branches out beyond single-stock browsing. Users can answer 10 questions to generate a portfolio matched to their risk comfort and goals. There’s an IPO section that digests bulky offer documents into a simpler verdict. It also includes a prompt-based screener that lets users search with simple phrases like “undervalued energy stocks” or “consistent profit growers” instead of creating manual filters from scratch.

And then there’s the trading interface itself. Trackk’s F&O product uses a single-screen layout. Users can tap a price block, choose buy or sell, set quantity and order type, and add target or stop-loss levels while tracking live position changes on the same screen. It’s simpler.

Who founded Trackk and what makes the team credible?

The founding story

Trackk was started in 2021 by Vedant Gupte, Siddharth Thakkar, and Aryan Jain. Vedant is the company’s CEO, while public company and profile records list all 3 founders as directors or key managerial personnel. The team’s pitch has stayed consistent: younger investors don’t behave like legacy brokerage users, so the product can’t look like a stripped-down version of an older trading terminal.

That belief wasn’t just branding. For its first 3 years, Trackk ran on top of Angel One’s APIs, with trade execution happening through that backend while the startup built its discovery and interface layer on top. It shows how Trackk started as a product-and-distribution wrapper, then moved toward becoming a deeper broking business in its own right.

Founder market fit

The founders are young, but they didn’t treat regulation like an afterthought. Vedant dropped out of Christ University and completed multiple NISM certifications tied to broking compliance, securities operations, and derivatives. Aryan Jain studied at Jai Hind College and holds NISM certifications spanning compliance, operations, investment advisory, and research analysis. It’s the kind of boring but essential groundwork a licensed retail broker has to get right.

That hands-on regulatory work showed up in public milestones. By October 2025, Trackk had become one of India’s youngest registered brokers and was felicitated at the Bombay Stock Exchange. For a startup selling simplicity to first-time investors, that broker status isn’t cosmetic. It’s the bridge between nice discovery UX and actual market participation.

Traction, fundraising, and positioning

Trackk’s official company pages list 130k users and a 4.7-star App Store rating, and nearly 90% of its users are between 20 and 24 years old. That’s a narrow audience by design, not a weakness. Frankly, a lot of consumer fintechs say they’re for “everyone” and end up meaning no one.

The fresh round brings in Lightspeed as lead investor, plus Info Edge Ventures and angel backers named in the source article including Tanmay Bhat, Gaurav Munjal, Roman Saini, Varun Mayya, and Tanay Pratap. Trackk will use the money for broking infrastructure and user acquisition. New financial products are also on the list. Earlier reporting indicates the startup had raised about $1.7 million before this from investors including MGA Ventures, GSF Ventures, GNP Group, Paras Defence, and angel investors.

Competition is the hard part. India’s retail brokerage market is still defined by much bigger names like Groww, Zerodha, Angel One, and Upstox, while INDmoney and Dhan push hard on adjacent wealth and active-trader use cases. Trackk’s differentiation isn’t price leadership or scale — at least not yet. It’s a discovery-first product for young users who want stock ideas, portfolio cues, prompt-based screening, and execution in one flow rather than in disconnected layers.

Why does this Trackk funding round matter?

This round matters because it gives Trackk a shot at graduating from a clever interface layer into a fuller-stack financial product. If the startup spent its first phase proving it could get young users to discover stocks differently, the next phase is about controlling more of the plumbing — onboarding, broking, execution, and whatever comes after plain-vanilla equity investing. That’s a much tougher build. But it’s where the value sits.

There’s also a strong signal in who showed up on the cap table. Lightspeed has backed plenty of Indian consumer internet bets, and Info Edge Ventures tends to like categories where distribution behavior is shifting before incumbents fully adjust. Pair that with a founder line that discovery now happens through creators and communities, and the thesis comes into focus: Trackk isn’t just another broker app. It’s trying to become the default financial interface for a generation that learned markets through content first, not through broker websites or research desks.

Its roadmap points the same way. Trackk is building toward a broader multi-asset platform covering investing, wealth creation, and other financial products for younger Indians. The real test after this seed round won’t be downloads. It’ll be whether the company can turn a youthful stock-discovery habit into a durable financial relationship.

How big is the market for the Trackk trading app?

The addressable market is a lot bigger than current penetration suggests. SEBI’s 2025 investor survey found that 63% of Indian households are aware of at least one securities-market product, but only 8.5% actually hold a demat account. The same survey found that 74% of non-investors cite complexity and information gaps as a barrier, 73% worry about risk and returns, and 56% say social media is the leading awareness channel. That’s a strong demand brief for a startup trying to simplify investing for a digital-native audience.

The raw user base is still rising too. One recent prospectus filing cited in search results pegged India’s total demat accounts at 192.4 million in FY2025 and 207.1 million in H1 FY2026. So even with regulatory tightening in derivatives and softer retail trading activity at some large brokers, the long-term retail-participation curve still points up.

Zoom out a bit and the money pool is huge. IMARC estimates India’s wealth-management market was worth $171.16 billion in 2025 and could reach $436.4 billion by 2034. Trackk won’t capture anything close to that on its own. But if even a modest slice of new retail wealth formation is shaped by mobile-first, low-friction products, startups like this have room to matter.

Will the Trackk trading app stand out in Indian wealthtech?

That depends on whether Trackk can keep its product sharp while getting more boring under the hood.

And yes, boring is good here. Compliance, execution quality, stable broking infrastructure, and responsible product design matter way more than cool brand language once real money is involved.

The Trackk trading app already has one useful advantage: it understands that young investors don’t want less information, they want cleaner information. If the company can turn that insight into trust — not just engagement — this round could look smart in hindsight. What to watch next is simple: how fast it expands its own broker stack, whether multi-asset products actually ship, and if its Gen Z users stay once the novelty wears off.

Read how Kin Health raised a $9M seed led by Maveron to build an AI medical notetaker for patients, helping people leave doctor visits with clear, usable records instead of confusion and scattered instructions.

FAQ

– What is the latest Trackk funding round? 

 Trackk has raised $3.7 million in a seed round led by Lightspeed, with Info Edge Ventures also participating. The round also included angel investors named in the source article, and the company plans to use the capital for broking infrastructure, user growth, and new financial products.

– How does the Trackk trading app work for beginners? 

 It starts with discovery, not execution. Users can look up a stock, read a simplified report with verdicts and risk signals, build a portfolio after answering 10 questions, review IPO analysis, and use plain-English prompts to create screeners instead of manually setting dozens of filters.

– Who founded Trackk and when was it started? 

 Trackk was founded in 2021 by Vedant Gupte, Siddharth Thakkar, and Aryan Jain in Mumbai. Vedant is the CEO, and public records show the founders built the company while getting the regulatory and operational credentials needed to run a licensed broking business.

– Why are investors interested in Gen Z wealthtech startups like Trackk? 

 Because the demand pattern is changing fast. SEBI’s 2025 survey shows awareness of market products is much higher than actual participation, and many non-investors still say the process feels too complex — which creates room for apps that simplify discovery, education, and execution for younger users who already live on mobile and social platforms.

Kin Health is building an AI medical notetaker for patients. The Los Angeles startup has raised a $9 million seed round led by Maveron. Doctor visits are often packed with instructions, jargon, and follow-ups. But many patients still leave without a clear record they can actually use.Kin was founded by physician brothers Arpan Parikh and Amit Parikh alongside HeyDoctor co-founder Kyle Alwyn. The startup believes the next useful healthcare AI product will focus on patients, not clinic admin teams.

That’s a smart angle.

A lot of healthcare AI has been built to help providers document faster, code faster, and bill faster. Kin is going after a different user. That makes this seed round more interesting than a standard “another scribe startup got funded” story.

What does Kin Health’s AI medical notetaker do?

Kin works like a meeting recorder built for medical appointments. A patient taps record during an in-person or telehealth visit. The app captures the conversation, then turns that recording into a plain-English summary plus a list of concrete next steps. It also keeps those visit records together over time, so the app starts to function like a portable, patient-controlled health record rather than a pile of disconnected appointment memories.

The workflow is more detailed than the source article first suggests. Kin lets users write down questions before a visit and sends reminders ahead of appointments. It also supports sharing summaries with a “Care Circle” of family or caregivers using different permission levels. Recent app updates added a U.S. provider directory, calendar-based visit detection, summary-ready notifications, and lock-screen support. That’s a clear sign the team wants the product to feel like a daily utility, not just a recording tool you forget about after one visit.

Under the hood, Kin runs through multiple layers: first transcription, then conversion into a clinical narrative, then a patient-facing summary with action items. The company relies on specialized medical models and checks outputs at different stages to improve accuracy. That matters. Messy summaries are worse than no summary at all in healthcare.

Privacy is a big part of the pitch too. Recording only starts when the patient actively starts it. Summaries stay private unless the user shares them, and visits can be deleted at any time. Kin isn’t a HIPAA-covered entity in the same way a provider is, but it follows the same privacy standard and doesn’t sell or share patient data without the user’s knowledge.

Who founded Kin Health and what’s the company background?

The founding story

Kin came together around a pretty specific frustration: patients often walk out of the most important moment in their care — the doctor conversation itself — with no reliable record of what they were told. Arpan and Amit Parikh are practicing physicians and brothers, and Kyle Alwyn had already built consumer health software before. GoodRx co-founders Doug Hirsch and Trevor Bezdek joined as founding partners and executive chairmen, which gives the startup a very obvious consumer-health lineage from day 1.

Arpan Parikh is also serving as CEO, while Alwyn is CTO. The company’s public materials frame Kin less as a one-off note generator and more as the beginning of a broader “health graph” that can pull together information from multiple sources and eventually help drive follow-through. That ambition is bigger than summarization. It’s trying to turn scattered health information into something a patient can act on.

Why this team fits the problem

The physician founders give Kin credibility on the clinical side. Arpan is a double board-certified physician with experience building healthcare services companies and direct caregiver experience. Amit is also a double board-certified physician with experience leading product organizations, which is unusual and useful — a lot of clinicians have domain knowledge, but not product instincts.

Alwyn brings the consumer product piece. He co-founded HeyDoctor, an online prescription and virtual care service that GoodRx acquired, and Kin’s official materials describe him as an engineering leader who has shipped consumer health products. Even his public profile hints at the same blend — software architecture, experience design, and consumer product work. That’s relevant because Kin has to be easy enough for patients to use during a stressful appointment, not just technically impressive.

Fundraising, launch status, and early signals

The company has raised $9 million in seed financing, with Maveron leading the round. Other backers include Town Hall Ventures, Eniac Ventures, Flex Capital, Foundry Square Capital, Pear VC, and The Family Fund. Hirsch and Bezdek also invested, along with angel investors Jay Desai, Nabeel Quryshi, Alex Cohen, Saharsh Patel, and more than 30 physicians.

Kin is headquartered in Los Angeles, and the app is already live in the Apple App Store and Google Play. On iPhone, the first public version appeared on April 23, 2026, with follow-on updates rolling out quickly afterward. We don’t get hard user numbers from that, but it does show this isn’t a concept deck raising on future promises alone.

The business model is also deliberate. Kin says the app will stay free for patients forever and will monetize through referrals to downstream services such as specialists, labs, and prescriptions. It’s basically a page borrowed from the GoodRx playbook. That’s clever if it works. It removes consumer price friction, but it also means Kin eventually has to prove it can become a trusted gateway for care decisions, not just a nice utility.

How Kin Health compares with competitors

Here’s the real distinction: most of the obvious competitors are built for clinicians, not patients. Heidi Health, Freed, Abridge, Nabla, Nuance, and Suki all live closer to the provider workflow, where the goal is usually documentation relief, note drafting, or EHR-friendly summaries. Heidi, for example, has positioned itself as an AI medical scribe for providers and larger health systems, with integrations into clinical software and a later $65 million Series B after its earlier Series A.

Kin’s alternative isn’t just those startups. It’s also the old mess: half-remembered advice, handwritten notes, patient portals that don’t explain much, and family members trying to reconstruct instructions from memory in the parking lot. Its differentiators are portability across providers and patient control over recording and sharing. Caregiver collaboration is part of it too. The product is free and isn’t tied to a single health network or EHR. That’s the “massive distribution advantage” Maveron is betting on.

Why does Kin Health’s $9M seed round matter?

This round matters because it gives Kin room to become more than a recording app. The company will use the money to deepen its consumer product and expand its health record capabilities. It also plans to build what it calls a clinical quality and rigor engine and start rolling out downstream care navigation features. During 2026, it plans to pull in data from additional health sources, including physician notes through EHR systems.

That roadmap gets to the hardest part of this category. Summaries are easy to demo. Trust is hard to earn. Mass General Brigham’s Rebecca Mishuris put it bluntly in comments carried by the original reporting: generative AI hallucinates, and clinicians still need to review anything that touches documentation. Kin doesn’t currently put itself in the clinician-signoff loop the way provider scribes do, but accuracy still matters because patients may act on what the app tells them to do next. Seed money helps, but it doesn’t solve that burden by itself.

There’s also a strategic signal in who wrote the check. Maveron has long liked consumer brands and products that can reach users directly. Kin fits that thesis more cleanly than most health AI companies because it doesn’t need a hospital procurement cycle to get started. If patients adopt it on their own, the company can build distribution from the bottom up and bring providers along later. It’s a very different bet from enterprise healthcare software.

How big is the AI medical notetaker market?

The timing here isn’t random. Menlo Ventures said the ambient scribe market hit $600 million in 2025, up 2.4x year over year, and called it one of the clearest areas of healthcare AI demand. The same report said healthcare captured $1.5 billion of vertical AI investment in 2025 — about 43% of the category total. Investors clearly think documentation and workflow automation are where real spending is already happening.

Kin is showing up as provider-side adoption is already well underway. In its funding announcement, the company cited ambient scribe adoption of 75% to 90% within major health systems, which helps explain why a patient-facing version now feels timely rather than weirdly early. There’s also a gigantic usage base to target: patients in the U.S. go to about 1 billion physician appointments every year. Even capturing a tiny slice of those visits could build a very large consumer health product.

What to watch next for Kin Health’s AI medical notetaker

Kin has a sharp idea and a founder lineup that makes sense for it. But this is still a tough product to get right, because the bar isn’t just usability — it’s clarity, privacy, and enough accuracy that patients actually trust it in the moments that matter.

The next thing to watch is whether Kin can turn its AI medical notetaker into a broader action layer for care without drifting into overreach. If EHR connections land, referrals start working, and patients keep using it between visits instead of only during them, Kin could end up creating a real new category in consumer health.

Read how Cellogen Therapeutics raised ₹20 crore from Kotak Alternate Asset Managers to build lower-cost CAR-T and gene therapies aimed at making advanced cancer treatment more affordable and accessible.

FAQ

– What funding did Kin Health raise?  

 Kin Health raised a $9 million seed round led by Maveron in May 2026. The round also included Town Hall Ventures, Eniac Ventures, Flex Capital, Foundry Square Capital, Pear VC, The Family Fund, GoodRx leaders Doug Hirsch and Trevor Bezdek, several angels, and more than 30 physicians.

– How does Kin Health’s app work?  

 The app records a doctor visit, transcribes the conversation, and turns it into a plain-language summary with next steps for the patient. It also supports pre-visit question prep and caregiver sharing. Appointment reminders and newer features like provider lookup and calendar-based visit detection are part of the product too.

– Who started Kin Health?  

 Kin Health was started by Arpan Parikh, Amit Parikh, and Kyle Alwyn, with GoodRx co-founders Doug Hirsch and Trevor Bezdek involved as founding partners and executive chairmen. The Parikh brothers are practicing physicians, and Alwyn previously co-founded HeyDoctor, which GoodRx acquired.

– Is Kin Health part of the AI scribe market or something different?  

 It sits adjacent to the AI scribe market, but the audience is different. Most AI scribes such as Heidi, Abridge, Nuance, Nabla, and Suki are sold to clinicians or health systems, while Kin is built for patients who want their own record of a visit and a clearer sense of what to do next.

Cellogen Therapeutics is building lower-cost CAR-T and gene therapies for cancer and blood disorders, and it has now pulled in ₹20 crore from Kotak Alternate Asset Managers. The big problem it’s chasing is brutally simple: existing CAR-T treatment can cost $500,000 to $700,000, which puts it out of reach for most patients. Founded in 2021 by Dr. Gaurav Kharya and Dr. Tanveer Ahmad, the company wants to push that price down to $60,000 to $70,000. That’s a huge claim.

What does Cellogen Therapeutics actually build?

Cellogen Therapeutics is a cell and gene therapy startup working on next-generation CAR-T treatments that try to solve two old problems in cancer immunotherapy: relapse after the cancer stops showing a single target, and weak long-term persistence of the modified T cells. For a patient, the treatment flow still follows the familiar CAR-T route. Immune cells are collected and engineered, expanded in a GMP setup, and infused back. The difference is in the design of the CAR itself.

Instead of sticking to a one-marker attack, Cellogen has built bispecific CAR-T constructs that go after 2 tumor antigens at once. Its work has centered on combinations such as CD19-CD20 and CD19-CD22. It has also tested different co-stimulatory domain mixes including CD28, 4-1BB, ICOS, and OX40. That’s the company’s core technical bet: if cancer slips past one marker, the second target gives the therapy another shot at killing it.

And it didn’t get there by tinkering around the edges. Cellogen designed almost 50 CAR constructs in preclinical work, narrowed that down to 2 better-performing candidates, and then pushed those into animal studies. Its preclinical work points to stronger tumor kill, proliferation, and persistence than standard CD19-focused second-generation CAR-T approaches. The science is interesting. The hard part, as always, is proving that in humans.

There’s a second product thread here too. Beyond cancer, Cellogen is building gene-editing programmes for beta thalassemia and sickle cell disease. The approach targets BCL11A to recreate mutations associated with hereditary persistence of fetal hemoglobin, using lentiviral and CRISPR-based methods. In plain English: it’s trying to switch fetal hemoglobin back on, because higher HbF levels can blunt disease severity in both conditions.

Who founded Cellogen Therapeutics and what has it done so far?

The founding story

Cellogen was established on 8 June 2021. Dr. Gaurav Kharya and Dr. Tanveer Ahmad started the company to build cell and gene therapies inside India instead of depending on imported science and imported pricing. That shows up in the company’s pitch pretty clearly — it isn’t just trying to make CAR-T work. It’s trying to make it local enough and cheap enough to actually get used.

The company began with hematological cancers and blood disorders, then expanded its pipeline into hemoglobinopathies. It also built research ties early, including collaborations with CSIR-IGIB in Delhi, DBT-RCB in Faridabad, CSIR-IICB in Kolkata, and later CMC Vellore for clinical progress.

Why the founder-market fit is real

Kharya brings actual bedside credibility to this. He’s a pediatric hematology, oncology, and immunology specialist who has led bone marrow transplant and cellular therapy work in India. Before Cellogen, he built deep experience in stem cell transplant, sickle cell disease, and blood cancers, and he has worked on more than 1,000 transplants across different conditions. He’s also been involved in CAR-T and gene-therapy research for hemoglobin disorders. That makes this startup feel less like a financial bet dressed up as science and more like a clinician trying to fix a broken cost structure.

That matters because cell therapy companies don’t just need a cool slide deck. They need someone who understands toxicities and manufacturing constraints. Patient selection matters too. So do donor issues and what happens when a trial protocol meets a real hospital.

Early signals and product status

Cellogen is still early. Its lead CAR-T programme is moving toward Phase I human clinical trials, subject to regulatory approvals, in collaboration with CMC Vellore. In 2025, it also secured a patent for its CAR-T platform, which gives it some defensibility as it inches toward the clinic.

The public team page shows a bench-heavy organisation, with staff across manufacturing, QC, QA, R&D, computational biology, and operations. That’s what you want to see from a biotech trying to get out of the lab and into regulated production. Not flashy. Useful.

The funding stack

The fresh capital came from Kotak Alts through Kotak Life Sciences Fund I, or KLSF-I. Cellogen will use the money to advance CAR-T clinical programmes, expand the gene therapy pipeline, and build out GMP-compliant manufacturing plus regulatory capability.

This didn’t come out of nowhere. Natco Pharma had already bought a stake of a little over 5% in Cellogen for ₹15 crore. KLSF-I itself isn’t a one-off vehicle built around a single hot theme. The fund marked its first close in January 2025 at ₹250 crore, with backing from family offices, ultra-high-net-worth individuals, industry veterans, and institutions. It invests across life sciences and medical devices. Digital health, diagnostics and delivery, and consumer wellness are also in scope. In February 2026, it also led a ₹65 crore round in ZeroHarm Sciences alongside Alkemi Growth Capital.

Can Cellogen beat other India CAR-T companies?

That won’t be easy.

ImmunoACT is already much farther down the road. It won market authorization for NexCAR19 in 2023, moved into commercial infusion after that, and has been building a wider hospital network since. Immuneel has also spent years building integrated cell therapy infrastructure in Bengaluru, with a facility designed around autologous cell therapies including CAR-T for leukemia and lymphoma.

So where does Cellogen try to stand apart? On 2 things: price and design.

On price, it wants to bring therapy down toward $60,000 to $70,000. On design, it’s using dual-antigen targeting to reduce relapse risk compared with older single-target CAR-T products. If that holds up clinically, investors aren’t just backing another Indian CAR-T hopeful. They’re backing a version that could compete by being both cheaper and more resilient against antigen escape.

Why are investors backing Cellogen Therapeutics now?

Because this round is less about scale-up vanity and more about crossing the ugliest part of biotech company building.

Cellogen now has enough backing to push work that investors usually treat as make-or-break: clinical prep, GMP manufacturing, and regulatory execution. Those are the expensive, boring, absolutely unavoidable pieces that separate a science project from a therapy company. A lot of startups look exciting right until they hit this wall.

The timing lines up with Cellogen’s own roadmap. It already has preclinical data, institutional research partnerships, a patent, and a clinical collaboration with CMC Vellore. That doesn’t guarantee success. It does mean the company has moved past the “interesting hypothesis” stage.

Kotak’s interest also tells you something. This isn’t tourist capital chasing biotech because it sounds futuristic. KLSF-I is built for early- and growth-stage healthcare bets. So the thesis here looks pretty direct: India needs advanced therapies that don’t import Western price tags, and Cellogen might be one of the teams able to build that locally.

How big is the India CAR-T therapy market?

Pretty big already. And still early.

India’s CAR-T cell therapy market was valued at about $534.8 million in 2024 and is projected to reach roughly $1.22 billion by 2033. That’s not small niche-science money anymore. It’s the kind of number that starts attracting serious manufacturing, clinical, and institutional capital.

The broader biotech setup in India also helps. The country now has more than 11,000 biotech startups, and the policy mood has shifted toward higher-value biopharma rather than just generic scale. In the Union Budget for 2026-27, Finance Minister Nirmala Sitharaman announced the Biopharma SHAKTI scheme with an outlay of ₹10,000 crore over 5 years. The plan includes support for talent and clinical infrastructure. It also aims to strengthen regulatory capacity, with a nationwide network of 1,000-plus accredited clinical trial sites in view.

That doesn’t magically solve cell therapy manufacturing, reimbursement, or hospital readiness.

But it does mean startups like Cellogen are launching into a market with some policy tailwind behind it.

What to watch next for Cellogen Therapeutics

Cellogen Therapeutics has a sharp pitch: better CAR-T design and far lower pricing. It also has an India-first manufacturing mindset. That’s compelling. It’s also unproven where it matters most — in human data.

So the next real checkpoint isn’t another funding headline. It’s whether Cellogen can get into the clinic, clear regulatory hurdles, and show that its dual-antigen CAR-T logic translates into durable outcomes for patients.

Read how Nectar Social raised a $30M Series A led by Menlo Ventures and the Anthology Fund to build an AI-powered social operating system that helps brands manage community conversations, creator workflows, and commerce across modern platforms.

FAQ

– What funding did Cellogen Therapeutics raise? 

 Cellogen Therapeutics raised ₹20 crore from Kotak Alternate Asset Managers. The investment was made through Kotak Life Sciences Fund I, and it followed an earlier ₹15 crore investment from Natco Pharma, which gave Natco a stake of a little over 5% in the company.

– How does Cellogen Therapeutics’ CAR-T platform work? 

 Cellogen is developing CAR-T therapies that target 2 cancer markers instead of just 1. Its lead constructs focus on combinations such as CD19-CD20 and CD19-CD22, which are meant to reduce relapse caused by antigen escape and improve how long the engineered T cells stay active.

– Who founded Cellogen Therapeutics? 

 Cellogen was founded in 2021 by Dr. Gaurav Kharya and Dr. Tanveer Ahmad. Kharya is a pediatric hematology and bone marrow transplant specialist with deep experience in blood disorders, stem cell transplant, and cellular therapy, which gives the company unusually strong clinical grounding for an early-stage biotech.

– Is Cellogen Therapeutics in the CAR-T therapy market or the gene therapy market? 

 It’s in both. Cellogen’s main focus today is CAR-T therapy for cancers, but it’s also building gene-editing programmes for beta thalassemia and sickle cell disease, which puts it squarely inside the broader cell and gene therapy category.

Nectar Social builds software that helps brands handle community management and social listening. It also covers creator workflows and commerce conversations in one place. That AI social OS just brought in a $30 million Series A led by Menlo Ventures and the Anthology Fund, which Menlo created alongside Anthropic. The pitch is simple: buying conversations are happening inside comments, DMs, Reddit threads, and short-form video, while most marketing teams still juggle too many tools to keep up. Nectar Social was founded in 2023 by sisters Misbah Uraizee and Farah Uraizee, both former Meta leaders, and the new money is meant to speed up hiring across applied AI, engineering, and go-to-market.

What is Nectar Social’s AI social OS?

Nectar Social is trying to turn social from a messy set of inboxes and dashboards into one operating layer for marketers. A brand can use it to monitor comments, messages, stories, videos, and broader conversation signals across platforms. Then it routes those interactions into workflows that support moderation, customer care, creator management, and sales. It doesn’t just show teams what happened. It acts on it.

The workflow is more specific than a generic “AI assistant” pitch. Nectar breaks it into analyze, train, test, and deploy. First it pulls in social conversations and performance data, then surfaces sentiment shifts, emerging topics, share of voice, and feedback themes. After that, teams can train workflows with brand voice rules, auto-tagging, and routing logic. They can test responses against historical messages with human review and guardrails, then push automation live across channels.

The feature list goes beyond reply generation. Nectar includes competitive benchmarking and earned media value tracking. It also offers multimodal video analysis, post-level performance insights, conversion tracking, and connected purchase analytics. It plugs into downstream tools like Klaviyo and Attentive, so a brand isn’t just answering social messages faster. It can retarget users, measure outcomes, and tie conversation back to revenue.

Here’s the before-and-after. In the old setup, a social team might use one tool for listening, another for publishing, another for influencer work, and a CRM somewhere else. Nectar’s bet is that brands would rather run one system that can listen, respond, attribute, and learn in real time. Its data partnerships with Meta and Reddit matter because they let the platform pull platform-level signals into one view instead of forcing marketers to hop from tab to tab all day.

Who founded Nectar Social and what gives them an edge?

A sister-founded company built around a behavior shift

Nectar Social was founded in 2023 by Misbah Uraizee and Farah Uraizee. Misbah is the CEO. Farah is the CTO. The two started the company after seeing a change that a lot of legacy martech products still treat like a side feature: people increasingly discover products, ask questions, and make purchase decisions inside social conversations rather than on brand websites alone.

So Nectar doesn’t present itself as a scheduler with some AI bolted on. It’s built around the idea that social conversation is now part support desk, part focus group, part sales channel.

Why the founders fit this category

The sisters aren’t coming in cold. Both worked in product and engineering leadership roles at Meta, where they saw firsthand how consumer behavior was moving toward more private, conversational, and creator-led interaction. Misbah’s background included work across Facebook and Instagram feed and stories, plus messaging products. That matters. Nectar is selling into a workflow that sits right between social product design and commerce infrastructure.

Misbah also had product experience at X before starting Nectar. So the company’s worldview makes sense: social isn’t just a branding channel anymore. It’s where intent shows up early, often in messy, unstructured ways.

Execution track record and early signals

Nectar officially came out of stealth last year. It already counts brands including Liquid Death, Figma, and e.l.f. Beauty as clients, and the broader customer set shown by the company includes consumer brands that live or die on fast, high-volume engagement. That’s a useful signal because this kind of product only works if teams trust it with real interactions, not just sandbox demos.

It has also built direct data relationships with large platforms. A recent Reddit partnership adds Reddit community data into Nectar’s unified view alongside data from channels like Instagram, TikTok, YouTube, Facebook, and X. For a product built around community intelligence and commerce intent, that’s core infrastructure.

The funding stack — and what it says

The new round is a $30 million Series A. Menlo Ventures led it with its Anthology Fund, the vehicle Menlo created with Anthropic. Other investors in the round include Gwyneth Paltrow’s Kinship Ventures, GV, and True Ventures. That follows a $10.6 million seed round Nectar announced when it emerged from stealth, co-led by True Ventures and GV.

The capital is headed into hiring across applied AI, engineering, and go-to-market. That fits the product. An AI social OS isn’t just another SaaS dashboard. It needs reliable agent behavior and strong integrations. It also needs enough customer-facing support to get big brands comfortable with automation in public channels.

Where Nectar sits against Sprinklr, Sprout, and older tools

This is a crowded category. Sprinklr, Sprout Social, Khoros, Emplifi, and Brandwatch all cover parts of the same job, usually mixing publishing, listening, analytics, and care workflows. A lot of them now market their own AI layers.

Still, Nectar’s positioning is different enough to stand out. It’s pushing an AI-native model built around autonomous or semi-autonomous agents, unified community intelligence, and direct revenue attribution from social conversation. Legacy platforms were largely designed around dashboards, seats, and reporting. Nectar is trying to be the operating layer that actually executes. That’s a sharper pitch. It also means the company has to prove it can match incumbents on safety, reliability, and enterprise trust as it scales.

Why does this AI social OS funding matter?

This round matters because Nectar is moving past the “interesting seed startup” phase. Series A money tells customers and partners that the company has room to build a bigger product, hire faster, and survive long enough to become part of a serious martech stack. For brands, that lowers the risk of adopting a newer platform for a workflow that’s getting more central every quarter.

It also says something about investor appetite. Menlo’s involvement, plus the Anthology connection to Anthropic, suggests investors see real upside in software that uses AI agents for operational work, not just copywriting or analytics summaries.

Misbah Uraizee put the company’s argument plainly: “The buying conversation has moved into social, and no human team can staff every place it happens.” If Nectar is right, brands won’t just buy software to monitor social. They’ll buy software that helps them show up everywhere without exploding headcount.

How big is the market behind an AI social OS?

The numbers are big enough to explain why investors care. The global social media management market was estimated at about $24.8 billion in 2024 and is projected to reach roughly $85.1 billion by 2030. That’s a 23.2% compound annual growth rate from 2025 through 2030.

The category is also changing shape. Social teams used to focus heavily on publishing calendars, campaign reporting, and community moderation. Now they’re being pulled closer to commerce, customer care, creator programs, and real-time feedback loops. That widens the budget opportunity for products that can tie engagement to actual business outcomes.

Nectar showed up at the right moment. Social data is more fragmented, consumer journeys are less linear, and brands care a lot more about what happens in comments, DMs, and community threads than they did a few years ago. A plain listening tool doesn’t fully solve that. A plain CRM doesn’t either.

What should brands watch next from Nectar Social?

The next test isn’t whether Nectar can get headlines. It already did that.

The real test is whether this AI social OS can keep winning customers while staying accurate, brand-safe, and useful across a wider set of channels and enterprise workflows. If the company can turn its Series A into deeper integrations, better agent performance, and clearer revenue attribution, it could become more than another social tool. Watch the hiring pace, the product depth around applied AI, and whether bigger brands trust Nectar with more public-facing automation.

Read how Simple Energy raised ₹126.7 Cr led by Thyrocare founder Arokiaswamy Velumani to scale its premium electric scooter business and push toward a future IPO in India’s competitive EV market.

FAQ

– What did Nectar Social raise, and who backed it?  

 Nectar Social raised a $30 million Series A announced on Thursday. Menlo Ventures led the round through its Anthology Fund, and the investor list also included Kinship Ventures, GV, and True Ventures. That came after the company’s earlier $10.6 million seed.

– How does Nectar Social work for marketers?  

 Nectar Social works like an operating layer for social activity rather than a single-purpose dashboard. It pulls in conversation data from multiple channels and helps teams train brand-safe AI workflows. It tests those workflows with human oversight, then deploys automation for replies, routing, intelligence, and conversion tracking.

– Who founded Nectar Social?  

 Nectar Social was founded in 2023 by sisters Misbah Uraizee and Farah Uraizee. Misbah is the CEO and Farah is the CTO, and both came from Meta, where they held product and engineering leadership roles tied to large-scale social products.

– What market is Nectar Social competing in?  

 Nectar Social sits inside the social media management and martech category, but it’s pushing deeper into social commerce and community intelligence. That puts it up against older platforms like Sprinklr, Sprout Social, Khoros, and Brandwatch, while also trying to carve out a newer category around agent-driven social operations.